This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Results

Authoring team

Considering the primary endpoint, exercise tolerance at 12 weeks, omapatrilat and lisinopril are equivalent:

  • 24 sec increase in the omapatrilat group
  • 31 sec increase in the lisinopril group (p=0.45)

There was a significant effect on the secondary endpoint of death, admission or discontinuation of treatment due to worsening heart failure:

  • hazard ratio 0.52 (p=0.035)

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.